Dr Guei-Sheung Liu is a Principal Investigator and leads the Genetic Engineering Research unit at the Centre for Eye Research Australia (CERA). He also holds an adjunct Associate Professor position at the University of Melbourne and the University of Tasmania. Dr Liu has extensive expertise in genetic technologies with over 90 publications and continuous funding from the NHMRC and other agencies since 2012.

Dr Liu obtained his PhD in Biochemistry from the Kaohsiung Medical University (Taiwan). As a postdoc, he studied vascular pharmacology and tissue engineering at the O’Brien Institute and then continued his training at the CERA in ocular gene therapy. In 2017, Dr Liu was recruited by the University of Tasmania and established his own research group at the Menzies Institute for Medical Research. In 2021, Dr Liu returned to CERA and started a new research unit (Genetic Engineering Research Unit).

His current research work encompasses understanding ocular angiogenesis and leveraging those insights to develop novel genetic therapeutics that promise to transform the care of neovascular blinding diseases.  His research work has also extended into the fields of CRISPR/Cas-based gene engineering, with a focus to refine these applications to clear the current hurdles impeding clinical translation for ocular gene therapy with the objective to prevent vision loss in common, complex and rare inherited retinal diseases.

Editorial Board
Terms of Appointment: July 2022 - June 2024